Xantel, Inc. owns a manufacturing resource planning software system called AMAPS. Xantel licensed AMAPS to Schering-Plough, which later merged with Merck. The 1990 agreement contained a confidentiality provision prohibiting Schering-Plough from disclosing the software to any third party and prohibited the transfer or assignment of the license without Xantel’s consent.
In May 2010, Xantel filed suit against Merck, claiming breach of the confidentiality and non-assignment provisions. According to the complaint, Schering-Plough employees maintained the software system for several years, which was allowed by the agreement. But, in connection with an outsourcing to IBM, Schering-Plough terminated the employees who had been maintaining AMAPS, and those employees were hired by IBM who then began servicing the system. Xantel claimed that the system was then exposed to IBM who is a competitor.
Xantel advised Schering-Plough that maintenance of the system by IBM employees was a violation of the 1990 agreement and Xantel subsequently gave notice to Schering-Plough that the agreement was terminated and demanded the return of the system pursuant to the agreement. After Merck merged with Schering-Plough, Xantel filed suit against Merck for breach of contract and misappropriation of trade secrets. Xantel claimed that Schering-Plough violated the confidentiality provision when it allowed IBM to service the system and that Merck had not obtained consent from Xantel to use the system after it merged with Schering-Plough.
Please see full article below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.